英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

clientage    

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Neomorph | Molecular Glue Degraders
    Developing molecular glue degraders to accomplish what many have deemed impossible: the ability to target and destroy every disease-causing protein
  • Careers - Join Neomorph
    A neomorph is something entirely new—a trait not found in its predecessors That idea defines our name, and it defines our people Founded in San Diego, California, Neomorph is a team of builders committed to advancing bold science and translating discoveries into meaningful impact Our work is grounded in deep scientific rigor, careful experimentation, and disciplined decision-making, which
  • Terms of Use - neomorph. com
    Such risks and uncertainties include, among other things, the uncertainties inherent in pharmaceutical research and development; Neomorph’s ability to successfully complete pre-clinical or clinical development of its product candidates; decisions by regulatory authorities regarding whether and when to approve Neomorph product candidates
  • Privacy - Neomorph
    Neomorph will never rent, trade or sell your e-mail address However, we may on occasion share your name and postal address with our service providers, unless you opt-out Access to and Deletion of Information The accuracy of your PI is important to Neomorph
  • Neomorph Announces Closing of $100 Million Series B Financing
    SAN DIEGO, CA, Apr 13, 2026 (GLOBE NEWSWIRE) — Neomorph, Inc , a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the closing of a $100 million Series B financing
  • Contact Us - Neomorph
    Get in touch with Neomorph for partnerships, media inquiries or general questions
  • Neomorph Announces First Patient Dosed in Phase 1 2 Trial Evaluating . . .
    Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform SAN DIEGO, CA, Feb 3, 2026 (GLOBE NEWSWIRE) — Neomorph, Inc , a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the first patient has been dosed in the Phase 1 2 clinical trial (NCT07300241) evaluating NEO-811, a
  • AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue . . .
    Collaboration leverages AbbVie’s expertise in oncology and immunology drug development and Neomorph’s leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to $1 64B NORTH CHICAGO, Ill and SAN DIEGO, CA, Jan 23, 2025 PRNewswire –AbbVie (NYSE: ABBV) and Neomorph, Inc today announced a
  • Neomorph to Highlight Progress in Targeted Protein Degradation Science . . .
    Neomorph is a biotechnology company pioneering the discovery and development of molecular glue degraders to unlock new therapeutic possibilities across serious diseases By engineering neomorphic protein surfaces, Neomorph enables precision targeted protein degradation of disease drivers that have historically been considered undruggable





中文字典-英文字典  2005-2009